Abstracts Archive - Page 2360 of 2605 - ACR Meeting Abstracts

Abstract Number: 1065 • 2013 ACR/ARHP Annual Meeting
Acute Myocardial Infarction Variation Among U.S. Medicaid Recipients With Systemic Lupus Erythematosus By Race and Ethnicity, 2000-2006
Medha Barbhaiya¹, Candace H. Feldman¹, Jessica M. Franklin², Jun Liu³, Joanne M. Foody⁴, Michael A. Fischer², Daniel H. Solomon¹ and Karen H. Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA
Background/Purpose: SLE patients have elevated rates of acute myocardial infarctions (MI), but the sociodemographic groups that are most affected have not been well studied. We…
Abstract Number: 1066 • 2013 ACR/ARHP Annual Meeting
Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment
Cristina Drenkard¹, Charmayne M. Dunlop-Thomas², Gaobin Bao³ and S. Sam Lim⁴, ¹Department of Medicine, Emory University, Atlanta, GA, ²Medicine Rheumatology, Emory University, Atlanta, GA, ³Medicine, Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Depression can be found in 20-60% of SLE patients and has substantial impact on quality of life, disease outcomes and health care costs. Although…
Abstract Number: 1067 • 2013 ACR/ARHP Annual Meeting
Incidence and Prevalence Of Systemic Lupus Erythematosus: A 2010 Nation-Wide Population-Based Study Using French National Administrative Databases
Laurent Arnaud¹, Jean-Paul Fagot², Michel Païta², Alexis Mathian³, Anne Fagot-Campagna² and Zahir Amoura⁴, ¹Internal Medicine, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ²Caisse Nationale d’Assurance Maladie des Travailleurs Salariés, Paris, France, ³Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁴Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: To date, only a small number of studies have examined the epidemiology of systemic lupus erythematosus (SLE) on a nation-wide basis. These studies were…
Abstract Number: 1069 • 2013 ACR/ARHP Annual Meeting
Racial Differences In Systemic Lupus Erythematosus Patients’ Treatment Preferences: A Two-Site Study
Ernest R. Vina¹, Tammy O. Utset², Michael J. Hannon³, Nicole Roberts⁴, Christopher M. Masi⁵ and C. Kent Kwoh⁶, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA, ²Rheumatology, University of Chicago Medical Center, Chicago, IL, ³Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Internal Medicine, NorthShore University Health System, Evanston, IL, ⁶School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Racial disparities in systemic lupus erythematosus (SLE) exist, with African-American (AA) patients experiencing higher lupus damage scores and disease activity than white (WH) patients. …
Abstract Number: 1070 • 2013 ACR/ARHP Annual Meeting
Characteristics and Medication Use Patterns Among Belimumab Users In a Commercially Insured Population With Systemic Lupus Erythematosus
Xuehua Ke¹, Jeetvan Patel², Hong Kan², Debra F Eisenberg¹ and Alan Oglesby², ¹HealthCore Inc, Wilmington, DE, ²GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Belimumab is a B lymphocyte stimulator-specific inhibitor approved for treatment of systemic lupus erythematosus (SLE). The purpose of the study was to describe medication…
Abstract Number: 1071 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Systemic Lupus Erythematosus and Lupus Nephritis In The United States: Analysis Of Commercial and Public Insurance Billing Data
Kunal Gandhi¹, Evo Alemao¹, Hugh Kawabata¹ and Jan L. Hillson², ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Seattle, WA
Background/Purpose: Prevalence estimates of Systemic Lupus Erythematosus (SLE) in the U.S. vary, with numbers ranging from 161,000 (Helmick, 2008) to 1.5 million (Lupus Foundation of…
Abstract Number: 1032 • 2013 ACR/ARHP Annual Meeting
Shared Decision-Making In The Choice Of Biologic Medication: The Patient Perspective
Susan C. Bolge¹, Helen Eldridge² and Michael P. Ingham¹, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Services, LLC., Titusville, NJ
Background/Purpose: There has been increasing focus on the importance of patients participating in the treatment decision-making process with their physicians. Previous research has demonstrated that…
Abstract Number: 1033 • 2013 ACR/ARHP Annual Meeting
Psychological status correlates of disease activity and sleep quality in patients with Ankylosing Spondylitis: A case-control study
Mingcan Yang¹, Yutong Jiang², Zhiming Lin³, Zetao Liao⁴, Qiuxia Li⁴, Yanli Zhang¹ and Jieruo Gu⁵, ¹Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²Rheumatology, Third affiliated hospital of Sun Yat-sen University, Guangzhou, China, ³Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ⁴Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ⁵Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: The objective of this study was to compare psychological status and sleep quality between the patients with AS patients and healthy controls, and to discover the correlation between anxiety, depression and sleep disturbances, to evaluate the associated factors of disease specific variables in AS patients and to detect independent factors contributing to psychological variables. Methods: A nationwide face-to-face epidemiological investigation was performed in multiple centers of China. The demographic data , clinical symptoms/signs and psychological assessment data including Zung self-rating anxiety scale (SAS), Zung self-rating depression scale (SDS) and the Pittsburgh Sleep Quality Index questionnaire (PSQI) were collected using questionnaires. Mann-Whitney U test and t test was used in independent groups for parametric variables, whereas the Spearman correlation analysis and multiple stepwise regression analysis were used to assess correlation between parametric variables. Results: 683 AS patients by the revised New York criteria for AS and 697 age-, sex-, education-matched healthy controls were enrolled in the study.(1) Compared with healthy controls, AS patients suffered from more severe psychological disorders and sleep disturbance（P
Abstract Number: 1034 • 2013 ACR/ARHP Annual Meeting
The Part Of Function (Health assessment Questionnaire) In The SF-6D and EQ-5D Utility Measures Varies Over Time In Early Arthritis (ESPOIR cohort): Questionable Validity Of Deriving Quality Adjusted Life Years From HAQ
Cécile Gaujoux-Viala¹, Anne-Christine Rat², Kossar Hosseini³, Rene-Marc Flipo⁴, Francis Guillemin³ and Bruno Fautrel⁵, ¹EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ³CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Rheumatology, University Hospital Lille, Lille, France, ⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: There is growing emphasis on the cost-effectiveness of treating early arthritis (EA). As few studies directly record the utility measures needed for economic analyses,…
Abstract Number: 1035 • 2013 ACR/ARHP Annual Meeting
Psoriatic Arthritis and Mortality – a Nationwide Study
Thorvardur Jon Love^1,2, Thor Aspelund³, Alexis Ogdie⁴, Joel M. Gelfand⁵, Hyon K. Choi⁶, Vilmundur Gudnason³ and Bjorn Gudbjornsson², ¹Landspitali University Hospital, Reykjavik, Iceland, ²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ³The Icelandic Heart Association, Kopavogur, Iceland, ⁴Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania., Philadelphia, PA, ⁶Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Psoriatic arthritis is an inflammatory arthritis that causes significant morbidity. While a study from a single research clinic in Canada published in the 1990´s…
Abstract Number: 1036 • 2013 ACR/ARHP Annual Meeting
The Independent Impact Of Depression On Incident Myocardial Infarction In Psoriatic Disease: A Population-Based Cohort Study
Lindsay C Burns^1,2, Jan P. Dutz¹ and Hyon Choi^3,4,5, ¹Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ²Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis (PsC) and psoriatic arthritis (PsA) represent common, lifelong inflammatory diseases of the skin and joints (respectively) that are associated with substantial cardiovascular and…
Abstract Number: 1037 • 2013 ACR/ARHP Annual Meeting
Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa)
Atsushi Hashimoto¹, Noriyuki Chiba², Jinju Nishino³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ³Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁴Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose :Patients with rheumatoid arthritis (RA) die mainly of cardiovascular/cerebrovascular diseases, respiratory diseases, infections, or malignancies. In recent years, the ratio of infections and respiratory…
Abstract Number: 1038 • 2013 ACR/ARHP Annual Meeting
Impact Of Biological Treatment On Overall Mortality and On Incidence Of Second Cancers In Arthritis Patients – A Follow-Up Study From The Danish Danbio Registry
Lene Dreyer¹, Lene Mellemkjær², Inger Marie Jensen Hansen³ and Merete Lund Hetland⁴, ¹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ²Danish Cancer Society Research Center, Copenhagen, Denmark, ³Department of Reumatology, OUH Svendborg Hospital, Svendborg, Denmark, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: It is largely unknown whether it is safe to treat arthritis patients with a previous malignancy with biologics. Only a few studies have address…
Abstract Number: 1039 • 2013 ACR/ARHP Annual Meeting
Risk Of High-Grade Cervical Dysplasia In Women With Systemic Inflammatory Diseases
Seoyoung C. Kim¹, Robert J. Glynn², Edward Giovannucci³, Sonia Hernandez-diaz⁴, Jun Liu⁵, Sarah Feldman², Elizabeth W. Karlson⁶, Sebastian Schneeweiss⁷ and Daniel H. Solomon^8,9, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard School of Publich Health, Boston, MA, ⁴Harvard School of Public Health, Boston, MA, ⁵Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁸Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Human papillomaviruses (HPV) are causes of high-grade cervical dysplasia and cervical cancer. Persistent HPV infection, the major risk factor for cervical cancer, is associated…
Abstract Number: 1040 • 2013 ACR/ARHP Annual Meeting
Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients
Siri Lillegraven¹, Jeffrey D. Greenberg², George W. Reed³, Katherine C. Saunders³, Jeffrey R. Curtis⁴, Leslie R. Harrold⁵, Marc C. Hochberg⁶, Dimitrios A. Pappas⁷, Joel M. Kremer⁸ and Daniel H. Solomon⁹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²NYU Hospital for Joint Diseases, New York, NY, ³Corrona, LLC., Southborough, MA, ⁴Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁷Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ⁸Center for Rheumatology, Albany Medical College, Albany, NY, ⁹Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Inflammation may contribute to diabetes risk, and some studies indicate that certain DMARDs might be associated with a reduced risk of diabetes. Most studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].